trending Market Intelligence /marketintelligence/en/news-insights/trending/iqz9M0Yy7LXH1Iapl67MDw2 content esgSubNav
In This List

Proteostasis, Roche's Genentech sign licensing deal worth approximately $100M

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Proteostasis, Roche's Genentech sign licensing deal worth approximately $100M

Proteostasis Therapeutics Inc. has agreed to grant the licensing rights of an undisclosed target to Roche Holding AG's unit Genentech Inc. for over $100 million including up-front and milestone payments.

According to Proteostasis Therapeutics, the agreement will not include its cystic fibrosis transmembrane conductance modulators, which were granted fast-track designation by the U.S. Food and Drug Administration in April, and other programs and medicines related to cystic fibrosis. Cystic fibrosis is a rare and inherited disease characterized by the buildup of sticky mucus in the lungs and digestive system, which leads to persistent lung infections and other complications.

Under the agreement, Genentech will bear future research and development costs related to the program, and Proteostasis Therapeutics will receive royalties. The companies have not disclosed the full financial terms, target program or disease areas of focus.

Cambridge, Mass.-based Proteostasis Therapeutics develops small molecule therapeutics that can address malfunctions in protein handling processes within the cells, which can cause a wide range of diseases, including cancer.